文献速递泌尿生殖介入USDSA

导管导向硬化治疗与卵巢囊肿切除术治疗单侧卵巢子宫内膜异位囊肿:一项初步随机对照试验

Catheter-Directed Sclerotherapy Versus Ovarian Cystectomy for Unilateral Ovarian Endometrioma: A Pilot Randomized Controlled Trial.
PubMed 文献 · AJR Am J Roentgenol · 2026-03-25

这项前瞻性初步随机对照试验纳入40例单侧单房子宫内膜异位囊肿(>3 cm)患者,比较氟透视及超声引导下导管导向硬化治疗(CDS)与腹腔镜囊肿切除术。CDS组12个月血清抗苗勒管激素(AMH)下降百分比小于囊肿切除组(14.9% vs 39.8%,p=.02),住院时间更短,疗效指标(囊肿大小、CA-125、EHP-30)两组无显著差异,CDS无并发症、囊肿切除组1例并发症,两组均无12个月复发。

要点

  • CDS组12个月AMH下降14.9%,囊肿切除组下降39.8%(p=.02),CDS对卵巢储备影响更小。
  • CDS组住院时间2.3±0.5天,短于囊肿切除组的4.2±0.7天(p<.001)。
  • 两组12个月CA-125和EHP-30评分无显著差异(p>.05),均无复发。

核心结论

  • CDS与囊肿切除术相比卵巢储备保护更好,疗效指标无显著差异;结果提升了支持CDS作为卵巢保留性囊肿切除替代方案的证据级别。

研究设计与样本

  • 前瞻性初步随机对照试验,纳入2021年3月至2024年7月评估的单侧单房子宫内膜异位囊肿(>3 cm)女性40例,随机分为氟透视及超声引导下CDS组(20例,平均年龄32.8岁)和腹腔镜囊肿切除组(20例,平均年龄35.1岁),主要终点为基线至干预后12个月血清AMH下降百分比。

关键影像表现/征象

  • 超声显示CDS组囊肿大小从基线5.8±1.5 cm降至12个月0.6±0.7 cm(p<.001),囊肿切除组从5.3±1.4 cm降至0.0±0.0 cm(p<.001)。
  • CDS组无并发症发生,囊肿切除组发生1例并发症。

诊断标准与关键数值

  • 主要终点12个月AMH下降百分比:CDS组14.9% vs 囊肿切除组39.8%(p=.02)。
  • CDS组AMH从3.1±2.2 ng/mL降至2.7±1.7 ng/mL(p=.08,未达统计学显著),囊肿切除组从3.3±3.0 ng/mL降至2.0±1.8 ng/mL(p<.001)。
  • CDS组CA-125从69.2±61.7 U/mL降至17.3±14.2 U/mL(p<.001),囊肿切除组从54.6±35.8 U/mL降至14.8±8.2 U/mL(p<.001),12个月两组间无显著差异(p>.05)。
  • CDS组EHP-30评分从31.3±12.8降至6.3±6.9(p<.001),囊肿切除组从34.5±18.0降至8.1±4.3(p<.001),12个月两组间无显著差异(p>.05)。

临床应用与阅片要点

  • 本试验中CDS在氟透视及超声引导下进行,适用于单侧单房子宫内膜异位囊肿且测量大于3 cm的患者。
  • CDS组住院时间2.3±0.5天,囊肿切除组4.2±0.7天(p<.001)。
  • 两组12个月均无复发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Ovarian cystectomy is the standard treatment of endometrioma but is associated with decreased ovarian reserve. Catheter-directed sclerotherapy (CDS) is an ovary-sparing image-guided alternative; however, supporting evidence comprises retrospective comparative and prospective single-arm studies. OBJECTIVE. The purpose of this study was to compare CDS and ovarian cystectomy in terms of therapeutic efficacy and effect on ovarian function in women with ovarian endometrioma through a randomized controlled trial. METHODS. This prospective pilot study enrolled women evaluated for unilateral unilocular endometrioma measuring greater than 3 cm from March 2021 to July 2024. Participants were randomized to treatment by fluoroscopically guided and ultrasound-guided CDS or laparoscopic cystectomy. The primary endpoint was percentage decline from baseline to 12 months after intervention in serum antimüllerian hormone (AMH) level (an ovarian functional reserve marker). Additional procedural and 12-month outcomes, including the Endometriosis Health Profile-30 (EHP-30) questionnaire addressing endometriosis-related symptoms and quality of life (lower score: better status), were assessed. RESULTS. The analysis included 40 participants: 20 randomized to CDS (mean age, 32.8 years) and 20 to cystectomy (mean age, 35.1 years). The mean 12-month percentage decline in AMH level (primary outcome) was smaller for CDS than cystectomy (14.9% vs 39.8%, respectively; p = .02). No complications occurred after CDS; one complication occurred after cystectomy. Hospital length of stay was significantly shorter after CDS (mean ± SD, 2.3 ± 0.5 days) than after cystectomy (4.2 ± 0.7 days) (p < .001). From baseline to 12 months, ultrasound-based cyst size significantly decreased for CDS (mean ± SD: from 5.8 ± 1.5 to 0.6 ± 0.7 cm; p < .001) and for cystectomy (from 5.3 ± 1.4 to 0.0 ± 0.0 cm; p < .001); mean AMH level was not significantly different for CDS (from 3.1 ± 2.2 [SD] to 2.7 ± 1.7 ng/mL; p = .08) but decreased significantly for cystectomy (from 3.3 ± 3.0 to 2.0 ± 1.8 ng/mL; p < .001); mean CA-125 level decreased significantly for CDS (from 69.2 ± 61.7 [SD] to 17.3 ± 14.2 U/mL; p < .001) and cystectomy (from 54.6 ± 35.8 to 14.8 ± 8.2 U/mL; p < .001); and mean EHP-30 score decreased significantly for CDS (from 31.3 ± 12.8 [SD] to 6.3 ± 6.9; p < .001) and cystectomy (from 34.5 ± 18.0 to 8.1 ± 4.3; p < .001). CA-125 level and EHP-30 score were not significantly different between groups at 12 months (p > .05). No 12-month recurrence occurred in either group. CONCLUSION. CDS was associated with better preservation of ovarian reserve versus cystectomy, without a significant difference in the therapeutic efficacy measures. CLINICAL IMPACT. These results advance the level of evidence supporting CDS as an ovary-sparing cystectomy alternative for appropriately selected patients. TRIAL REGISTRATION. ClinicalTrials.gov NCT05279209.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Hwang M, Seo SK, Kim MD, et al. Catheter-Directed Sclerotherapy Versus Ovarian Cystectomy for Unilateral Ovarian Endometrioma: A Pilot Randomized Controlled Trial. AJR Am J Roentgenol. 2026. PMID: 41879728. doi:10.2214/AJR.25.34498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。